Enoxaparin sodium
- Generic Name
- Enoxaparin sodium
- Brand Names
- Lovenox, Inhixa
- Drug Type
- Small Molecule
- CAS Number
- 9005-49-6
- Unique Ingredient Identifier
- E47C0NF7LV
- Background
Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies. Enoxaparin markedly reduces the incidence of venous thromboembolism in hospitalized patients when compared to unfractionated heparin, without increasing the risk of serious bleeding.
- Indication
Enoxaparin is indicated for the prevention of ischemic complications in unstable angina and in non Q-wave myocardial infarction; it is indicated in conjunction with percutaneous intervention and/or other treatment for the management of acute ST elevation myocardial infarction.
Enoxaparin is also indicated in the prophylaxis of DVT in abdominal surgery, hip replacement, knee replacement, or medical patients with severely restricted mobility during acute illness. Additionally, enoxaparin is indicated for the inpatient treatment of DVT with or without pulmonary embolism and the treatment of outpatient DVT without pulmonary embolism.
- Associated Conditions
- Acute Coronary Syndrome (ACS), Acute Myocardial Infarction With ST Segment Elevation, Deep Vein Thrombosis, Ischemic complications caused by non-q wave myocardial infarction, Ischemic complications caused by unstable angina
- Associated Therapies
- Percutaneous Coronary Intervention (PCI)
Dabigatran Etexilate in Extended Venous Thromboembolism (VTE) Prevention After Hip Replacement Surgery
- Conditions
- Arthroplasty, Replacement, HipThromboembolism
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 3494
- Registration Number
- NCT00168818
- Locations
- 🇦🇺
1160.48.06102 Monash Medical Centre, Clayton, Victoria, Australia
🇦🇺1160.48.06104 Ecru, Box Hill, Victoria, Australia
🇦🇺1160.48.06110 Suite 13 level 4, Lismore, New South Wales, Australia
RE-MODEL Dabigatran Etexilate 150mg or 220mg Once Daily (o.d.) Versus (v.s.) Enoxaparin 40mg o.d. for Prevention of Thrombosis After Knee Surgery
- Conditions
- Arthroplasty, Replacement, KneeThromboembolism
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2014-05-19
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2101
- Registration Number
- NCT00168805
- Locations
- 🇦🇺
1160.25.06103 Boehringer Ingelheim Investigational Site, Ringwood East, Victoria, Australia
🇦🇹1160.25.04303 Boehringer Ingelheim Investigational Site, Wels, Austria
🇨🇿1160.25.42010 Boehringer Ingelheim Investigational Site, Chomutov, Czech Republic
The Use of Low Molecular Weight Heparin in Traumatic Brain Injury
- Conditions
- Brain InjuryVenous Thrombosis
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-06-27
- Lead Sponsor
- Hennepin Healthcare Research Institute
- Target Recruit Count
- 300
- Registration Number
- NCT00170378
- Locations
- 🇺🇸
Hennepin County Medical Center, Minneapolis, Minnesota, United States
Dabigatran Etexilate vs Enoxaparin in Prevention of Venous Thromboembolism (VTE) Post Total Knee Replacement
- Conditions
- Arthroplasty, Replacement, KneeThromboembolism
- Interventions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2014-05-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 2615
- Registration Number
- NCT00152971
- Locations
- 🇲🇽
1160.24.05009 Traumatologia, Planta Baja, Guadalajara, Jalisco, Mexico
🇺🇸1160.24.01010 MIMA Century Research Associates, Melbourne, Florida, United States
🇺🇸1160.24.01033 Bone and Joint Clinic of Houston, Houston, Texas, United States
Michelangelo - Oasis 5
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 20078
- Registration Number
- NCT00139815
Which Therapy for Acute Heart Attacks? (The WEST Study)
- Conditions
- Myocardial Infarction
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- University of Alberta
- Target Recruit Count
- 300
- Registration Number
- NCT00121446
- Locations
- 🇨🇦
Queen Elizabeth II Hospital, Halifax, Nova Scotia, Canada
🇨🇦Grey Nuns Community Hospital, Edmonton, Alberta, Canada
🇨🇦Misericordia Hospital, Edmonton, Alberta, Canada
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
- Conditions
- Venous ThrombosisPulmonary Embolism
- Interventions
- First Posted Date
- 2004-11-23
- Last Posted Date
- 2010-03-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1238
- Registration Number
- NCT00097357
- Locations
- 🇵🇷
Local Institution, Ponce, Puerto Rico
Heparin or Enoxaparin in Patients With Cancer
- Conditions
- LymphomaThromboembolismUnspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2004-07-26
- Last Posted Date
- 2011-02-21
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 6
- Registration Number
- NCT00004875
- Locations
- 🇺🇸
Veterans Affairs Medical Center - Chicago (Lakeside), Chicago, Illinois, United States
🇺🇸Evanston Northwestern Health Care, Evanston, Illinois, United States
Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)
- Conditions
- Percutaneous Coronary Intervention
- First Posted Date
- 2004-02-18
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 3532
- Registration Number
- NCT00077844
PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)
- Conditions
- Acute Ischemic Stroke
- First Posted Date
- 2004-02-16
- Last Posted Date
- 2011-01-11
- Lead Sponsor
- Sanofi
- Registration Number
- NCT00077805
- Locations
- 🇹🇷
Sanofi-Aventis, Istanbul, Turkey
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.